Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1989 Sep-Oct;62(5):445–457.

The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.

G V Upton 1, A Corbin 1
PMCID: PMC2589161  PMID: 2534253

Abstract

Levonorgestrel (LNg) is known for its marked progestational/contraceptive activity. As shown in animal experiments, however, high doses of LNg are required to elicit an androgenic response; in contrast, considerably lower doses of LNg are required for antiovulatory (contraceptive) action. Thus, a large dose separation exists between androgenic and contraceptive activity. When LNg is combined with an estrogen, as in the contraceptive formulations, the androgenic response is attenuated or negated. The results of recent clinical trials have demonstrated that the androgenic activity of LNg is not expressed at contraceptive doses, particularly when LNg is combined with ethinyl estradiol (EE), as in the low-dose monophasic/triphasic formulations (monophasic [Nordette]: 150 mcg LNg/30 mcg EE; triphasic [Triphasil/Trinordiol]: six days, 50 mcg LNg/30 mcg EE; five days, 75 mcg LNg/40 mcg EE; ten days, 125 mcg LNg/30 mcg EE). Clinical evidence from several trials confirms that sex hormone-binding globulin levels are increased, plasma androgen levels are decreased, and acne is markedly improved with the use of Triphasil and Nordette, suggesting a non-androgenic profile.

Full text

PDF
445

Images in this article

453FIG. 4
on p.453

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beattie C. W., Corbin A. The differential effects of diestrous progestogen administration of proestrous gonadotrophin levels. Endocrinology. 1975 Oct;97(4):885–890. doi: 10.1210/endo-97-4-885. [DOI] [PubMed] [Google Scholar]
  2. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl. 1986;134:29–32. doi: 10.3109/00016348609157049. [DOI] [PubMed] [Google Scholar]
  3. Förström L., Mustakallio K. K., Dessypris A., Uggeldahl P. E., Adlercreutz H. Plasma testosterone levels and acne. Acta Derm Venereol. 1974;54(5):369–371. [PubMed] [Google Scholar]
  4. Gaspard U. J., Dubois M., Gillain D., Franchimont P., Duvivier J. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception. 1984 Apr;29(4):305–318. doi: 10.1016/0010-7824(84)90064-7. [DOI] [PubMed] [Google Scholar]
  5. HERSHBERGER L. G., SHIPLEY E. G., MEYER R. K. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med. 1953 May;83(1):175–180. doi: 10.3181/00379727-83-20301. [DOI] [PubMed] [Google Scholar]
  6. Jung-Hoffmann C., Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 1987 Jan;156(1):199–203. doi: 10.1016/0002-9378(87)90238-9. [DOI] [PubMed] [Google Scholar]
  7. Lim L. S., James V. H. Plasma androgens in acne vulgaris. Br J Dermatol. 1974 Aug;91(2):135–143. doi: 10.1111/j.1365-2133.1974.tb15858.x. [DOI] [PubMed] [Google Scholar]
  8. Lucky A. W. Endocrine aspects of acne. Pediatr Clin North Am. 1983 Jun;30(3):495–499. doi: 10.1016/s0031-3955(16)34397-8. [DOI] [PubMed] [Google Scholar]
  9. Odlind V., Carlström K., Michaëlsson G., Vahlqvist A., Victor A., Mellbin T. Plasma androgenic activity in women with acne vulgaris and in healthy girls before, during and after puberty. Clin Endocrinol (Oxf) 1982 Mar;16(3):243–249. doi: 10.1111/j.1365-2265.1982.tb00713.x. [DOI] [PubMed] [Google Scholar]
  10. Olsen T. G. Therapy of acne. Med Clin North Am. 1982 Jul;66(4):851–871. doi: 10.1016/s0025-7125(16)31398-0. [DOI] [PubMed] [Google Scholar]
  11. Palatsi R., Reinilä M., Kivinén S. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol. 1986;66(3):225–230. [PubMed] [Google Scholar]
  12. Upton G. V. The phasic approach to oral contraception: the triphasic concept and its clinical application. Int J Fertil. 1983;28(3):121–140. [PubMed] [Google Scholar]
  13. Vermeulen A., Thiery M. Metabolic effects of the triphasic oral contraceptive Trigynon. Contraception. 1982 Nov;26(5):505–513. doi: 10.1016/0010-7824(82)90149-4. [DOI] [PubMed] [Google Scholar]
  14. Woutersz T. B., Butler A. J., Cohen M., Korba V. D., Canavan R. C. A low-dose triphasic oral contraceptive. Fertil Steril. 1987 Mar;47(3):425–430. [PubMed] [Google Scholar]
  15. Woutersz T. B., Korba V. D. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive. Int J Fertil. 1988 Nov-Dec;33(6):406–410. [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES